- •Initiation with elexacaftor/tezacaftor/ivacaftor treatment might be associated with acute onset of systemic arterial hypertension.
- •Careful monitoring of cardiovascular paramenters is recommended in patients starting with elexacaftor/tezacaftor/ivacaftor treatment.
- •Referral may be made to cardiologists when patients present elevated blood pressure after the start with elexacaftor/tezacaftor/ivacaftor.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The future of cystic fibrosis care: a global perspective.Lancet Respir Med. 2020; 8 (JanEpub 2019 Sep 27. Erratum in: Lancet Respir Med. 2019 Dec;7(12):e40. PMID: 31570318): 65-124https://doi.org/10.1016/S2213-2600(19)30337-6
- Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.N Engl J Med. 2019; 381 (Nov 7Epub 2019 Oct 31. PMID: 31697873; PMCID: PMC7282384): 1809-1819https://doi.org/10.1056/NEJMoa1908639
- Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.J Cyst Fibros. 2021; 20 (MayEpub 2020 Jul 29. PMID: 32736949): 506-510https://doi.org/10.1016/j.jcf.2020.07.014
- Reduced blood pressure of CFTR-F508del carriers correlates with diminished arterial reactivity rather than circulating blood volume in mice.PLoS ONE. 2014; 9 (May 6PMID: 24801204; PMCID: PMC4011854): e96756https://doi.org/10.1371/journal.pone.0096756
- CFTR plays an important role in the regulation of vascular resistance and high-fructose/salt-diet induced hypertension in mice.J Cyst Fibros. 2021; 20 (MayEpub 2020 Dec 2. PMID: 33279469): 516-524https://doi.org/10.1016/j.jcf.2020.11.014